Présentation des projets sur le site web

Chaque projet soutenu par Gebert Rüf Stiftung est présenté sur le site web de la fondation avec en particulier les données de base du projet. Par cette publication, la fondation informe sur les résultats du soutien accordé et contribue à la communication scientifique au sein de la société.


PhagoVax – Combining Vaccination with Phage Therapy


The project management is responsible for the content of the information provided.

Données de projet

  • Numéro du projet: GRS-093/20 
  • Subside accordé: CHF 244'000 
  • Consentement: 29.10.2020 
  • Durée: 07.2021 - 12.2023 
  • Champs d'activité:  Microbials, seit 2016

Direction du projet

Description du projet

The inevitable evolution of resistance threatens the efficacy of antibiotics to fight pathogenic bacteria. However, alternatives to antibiotics remain scarce. We believe it is crucial to develop safe and affordable multi-pronged strategies that are robust to evolutionary changes in pathogenic bacteria. PhagoVax is the first attempt to combine vaccines with phage therapy in order to prevent or to cure infections by pathogenic bacteria.
The PhagoVax concept emerged from our recent discovery that vaccines can force a pathogen to lose its protection against phages (viruses that kill bacteria). Therefore, there should be no way for the targeted bacteria to escape eradication in vaccinated hosts treated with the right bacteriophage cocktail.
Our initial goal was to provide a sound proof of principle for this strategy in the mouse model by targeting Salmonella Typhimurium.

Etat/résultats intermédiaires

We were able to demonstrate the feasibility of a fundamentally new approach to fight pathogenic bacteria: carefully assembled bacteriophage cocktails can be used in combination with vaccination to improve the clearance of pathogenic bacteria from the intestinal tract of infected hosts. We found that this can also limit the transmission of pathogens, thereby diminishing the need for antibiotics. The obtained data are sufficient for patenting the Phagovax invention before publication and further developments of this approach in precliniacal models.
We obtained an additional two years funding to characterize the phage-bacterium co-evolution in the intestinal tract on mammals. This will be instrumental to refine the Phagovax approach against multi-resistant strains of pathogenic Escherichia coli, the leading cause of death attributable to antibiotic resistance.


Personnes participant au projet

Prof. Médéric Diard, University Basel, Biozentrum; project leader
Dr. Nicolas Wenner, project employee

External project partners:
Prof. Luisa De Sordi, Sorbonne Université
Dr. Marianne De Paepe, INRAe

Dernière mise à jour de cette présentation du projet  22.01.2024